METABOLISM OF DIACETYLPOLYAMINES AND CONTROL OF CELL PROLIFERATION

抗体特异性toN^1， N^8-二乙酰亚精胺（DiAcSpd）和N^1， N^<12>-二乙酰精胺（DiAcSpm）在兔中进行修饰，并使用亲和-1配体模拟DiAcSpm和DiAcSpd进行亲和纯化。Ant - diacspm抗体与N^1-乙酰亚精胺的交叉反应性仅为0.03%左右。建立了一种具有竞争力的ELISA检测系统，该系统使用高选择性的diAcSpm抗体。ELISA系统可准确测定低至10-20 nM的DiAcSpm浓度，且与HPLC测定值吻合良好。泌尿生殖系统恶性肿瘤患者尿液中DiAcSpm的测定结果表明：(1)除极早期外，大多数睾丸癌和肾癌患者尿液中DiAcSpm水平均较高。另一方面，在膀胱癌病例中，即使是晚期患者，DiAcSpm值也经常保持在正常范围内（健康人的平均值+ 2S.D）。(2)前列腺癌治疗后DiAcSpm水平与患者预后有较好的相关性。在治疗后DiAcSpm较低且稳定的病例中，即使有几个病例的PSA值仍然很高，患者的预后也很好。相反，当DiAcSpm在治疗后仍然升高时，患者的预后很差，即使治疗明显有效并暂时导致部分缓解。这些结果强烈提示DiAcSpm作为前列腺癌预后的良好指标，并且在这方面比PSA更好。

Antibodies specific toN^1, N^8-diacetylspermidine (DiAcSpd) AndN^1, N^<12>-diacetylspermine (DiAcSpm) were reised in rabbits and were affinity-pufified, using affinity-1 igands mimicking DiAcSpm and DiAcSpd. Cross-reactivity of Ant i-DiAcSpm antibody with N^1-acetylspermidine was only about 0.03%. A competitive ELISA system for the determination of urinary diAcSpm was developed, using this highly DiAcSpm-selective antibody. The ELISA system allowed accurate determination of DiAcSpm concentrations as low as 10-20 nM and the values obtained by this procedure coinceded very well with those determined by HPLC.Determination of the amount of DiAcSpm in the urine of patients with urogenital malignancies revealed several points as follows : (1) The DiAcSpm levels were high inmost testicular and renal cancer cases except for those at very early stages. On the other hand, in cases of bladder cancer, DiAcSpm values frequently stayed within the normal range (mean for healthy persons + 2S.D.) even with patients at advanced stages. (2) The DiAcSpm levels after treatments of prostate cancer were well correlated with the patients' prognosis. In cases where DiAcSpm was low and stationary after treatments, the prognosis of patients turned out to be favorable even though the PSA value remained high in several cases. In contrast, when DiAcSpm remained elevated after a treatment, prognosis of the patient was poor, even if the treatment had been apparently effective and had temporarily led to partial remission. These results strongly suggest that DiAcSpm serves as a good indicator of the prognosis of prostate cancer, and that it works much better than PSA in this respect.